Literature DB >> 14712487

Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients.

Vilmos Adleff1, Erika Hitre, István Köves, Zsolt Orosz, Anna Hajnal, Judit Kralovánszky.   

Abstract

Thymidylate synthase (TS) gene polymorphisms are important as prognostic factors in cancer chemotherapy, but recent results describe that the TS enhancer region (TSER) polymorphic genotypes may also modulate risk for malignancies. Two functionally important and ethnically diverse polymorphisms are present on the TS transcript, TSER, a repeat polymorphism (2 or 3 repeats; 2R, 3R) affecting TS expression, and a 6 bp ins/del polymorphism on the 3' UTR (position TS1494, del6 or ins6), which may influence mRNA stability. Hungarian population has one of the highest colorectal cancer (CRC) mortality rates in Europe, and several elevated dietary risk factors affect a large part of the population. In our study (99 primary CRC cases), population analysis of the patient group genotype frequencies revealed a departure from the Hardy-Weinberg equilibrium and significant heterozygote deficiency (p < 0.05) at the TSER locus. Despite the strong linkage between the 2 polymorphic loci, case TS1494del genotype frequencies were normally distributed, as well as the genotype frequencies of the healthy control population (n = 102), at both loci. Case-control comparison demonstrated a lower relative risk of TSER heterozygotes (OR = 0.47; CI = 0.27-0.83; p = 0.008) and a possible higher prevalence of the 3R3R&amp;ins6/del6 in the CRC group. The observation that heterozygotes are those less susceptible for CRC in the Hungarian population may support the possibility of 2 different pathways in which TS may play a role in colorectal carcinogenesis, probably nutrient (or folate)-dependently. The lack of similar genotype effect seen with TS1494del polymorphism and the increased presence of one genotype combination (3R3R&amp;ins6/del6) in the patient group suggest a possible TS haplotype effect influencing CRC risk. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14712487     DOI: 10.1002/ijc.11641

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  TYMS and DPYD polymorphisms in a Turkish population.

Authors:  H S Süzen; N Yüce; G Güvenç; Y Duydu; T Erke
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

2.  Genetic variants in the enhancer region of the thymidylate synthase gene in the Chilean population.

Authors:  M Acuña; L Eaton; L Cifuentes; D Massardo
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

3.  Polymorphisms of thymidylate synthase in the 5'- and 3'-untranslated regions and gastric cancer.

Authors:  Wen Zhuang; Xiao-Ting Wu; Yong Zhou; Guan-Jian Liu; Tai-Xiang Wu; Xun Yao; Liang Du; Mao-Ling Wei
Journal:  Dig Dis Sci       Date:  2008-11-07       Impact factor: 3.199

4.  Gene polymorphisms involved in folate and methionine metabolism and increased risk of sporadic colorectal adenocarcinoma.

Authors:  José Luiz Miranda Guimarães; Maria de Lurdes Ayrizono; Cláudio Saddy Rodrigues Coy; Carmen Silvia Passos Lima
Journal:  Tumour Biol       Date:  2011-05-21

5.  Evaluation of effects of thymidylate synthase and excision repair cross-complementing 1 polymorphisms on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood.

Authors:  Kaida Huang; Yan Shen; Fengqi Zhang; Shanshan Wang; Xiao Wei
Journal:  Oncol Lett       Date:  2016-04-07       Impact factor: 2.967

6.  The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.

Authors:  Moh'd Khushman; Girijesh Kumar Patel; Anu Singh Maharjan; Gwendolyn A McMillin; Cindy Nelson; Peter Hosein; Ajay P Singh
Journal:  Pharmacogenomics J       Date:  2021-02-19       Impact factor: 3.550

7.  Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.

Authors:  Vienna Ludovini; Cinzia Antognelli; Antonio Rulli; Jennifer Foglietta; Lorenza Pistola; Rulli Eliana; Irene Floriani; Giuseppe Nocentini; Francesca Romana Tofanetti; Simonetta Piattoni; Elisa Minenza; Vincenzo Nicola Talesa; Angelo Sidoni; Maurizio Tonato; Lucio Crinò; Stefania Gori
Journal:  BMC Cancer       Date:  2017-07-26       Impact factor: 4.430

8.  Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma.

Authors:  R A Hubner; J-F Liu; G S Sellick; R F A Logan; R S Houlston; K R Muir
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.